EP08.02-105 KRAS p.G12 Mutated Advanced Non-Small Cell Lung Cancer: Characteristics and Outcomes from a Danish Nationwide Observational Study
Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning › fagfællebedømt
Standard
EP08.02-105 KRAS p.G12 Mutated Advanced Non-Small Cell Lung Cancer : Characteristics and Outcomes from a Danish Nationwide Observational Study. / Frost, M.t.; Gotfredsen, D.r.; Petersen, T.s.; Jensen, K.j.; Solem, E.j.; Sørensen, A.m.s.; Louie, K.; Sroczynski, N.; Jakobsen, E.; Andersen, J.l.
I: Journal of Thoracic Oncology, Bind 17, Nr. 9, 2022, s. S451.Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - ABST
T1 - EP08.02-105 KRAS p.G12 Mutated Advanced Non-Small Cell Lung Cancer
T2 - Characteristics and Outcomes from a Danish Nationwide Observational Study
AU - Frost, M.t.
AU - Gotfredsen, D.r.
AU - Petersen, T.s.
AU - Jensen, K.j.
AU - Solem, E.j.
AU - Sørensen, A.m.s.
AU - Louie, K.
AU - Sroczynski, N.
AU - Jakobsen, E.
AU - Andersen, J.l.
PY - 2022
Y1 - 2022
N2 - IntroductionTreatment targeting the KRAS p.G12C (G12C) mutation was approved by both the U.S. Food and Drug Administration and the European Medicines Agency in the past year as second line of treatment (LOT2) for advanced non-small-cell lung cancer (aNSCLC). However, the treatment-eligible G12C mutant NSCLC population has not been well characterized, nor has its outcomes with current treatment approaches. The aim of this study was to characterize a nationwide real-world G12C mutant NSCLC population and to estimate its overall survival (OS) in Denmark.Section snippetsMethodsAdult aNSCLC patients diagnosed between January 1st, 2018 and October 31st, 2020 were identified in the Danish Lung Cancer Register. The register has captured data on all Danish lung cancer patients since 2003. Additional information was gathered from the following registers: the Danish National Patient Register, the Danish Pathology Register, the Danish Civil Registration System, the Danish National Prescription Register, the Danish Education Register, and the Income Statistics Register.ResultsWe identified 6,058 patients with aNSCLC. A total of 36.5% (n=2,214) were tested with next-generation sequencing (NGS) or polymerase chain reaction (PCR) tests for a KRAS mutation prior to LOT1. Among those tested, 40.5% (n=896) were KRAS mutated, 9.3% (n=206) were G12C mutated, and 39.0% (n=864) were KRAS/EGFR/ALK wild-type (Triple WT). Co-mutation with EGFR was present in 11% of G12C-mutated patients. Key characteristics and outcomes are presented in Table 1. TTNT was similar amongConclusionsThis Danish real-world study evaluating aNSCLC patients after the implementation of targeted therapy and immunotherapy showed that patients with a KRAS G12C mutation had a longer OS from LOT1 and LOT2 compared with Triple WT patients. The longer OS observed in patients with KRAS G12C mutant aNSCLC may be driven by higher PD-L1 expression and consequently more frequent use of immunotherapy.
AB - IntroductionTreatment targeting the KRAS p.G12C (G12C) mutation was approved by both the U.S. Food and Drug Administration and the European Medicines Agency in the past year as second line of treatment (LOT2) for advanced non-small-cell lung cancer (aNSCLC). However, the treatment-eligible G12C mutant NSCLC population has not been well characterized, nor has its outcomes with current treatment approaches. The aim of this study was to characterize a nationwide real-world G12C mutant NSCLC population and to estimate its overall survival (OS) in Denmark.Section snippetsMethodsAdult aNSCLC patients diagnosed between January 1st, 2018 and October 31st, 2020 were identified in the Danish Lung Cancer Register. The register has captured data on all Danish lung cancer patients since 2003. Additional information was gathered from the following registers: the Danish National Patient Register, the Danish Pathology Register, the Danish Civil Registration System, the Danish National Prescription Register, the Danish Education Register, and the Income Statistics Register.ResultsWe identified 6,058 patients with aNSCLC. A total of 36.5% (n=2,214) were tested with next-generation sequencing (NGS) or polymerase chain reaction (PCR) tests for a KRAS mutation prior to LOT1. Among those tested, 40.5% (n=896) were KRAS mutated, 9.3% (n=206) were G12C mutated, and 39.0% (n=864) were KRAS/EGFR/ALK wild-type (Triple WT). Co-mutation with EGFR was present in 11% of G12C-mutated patients. Key characteristics and outcomes are presented in Table 1. TTNT was similar amongConclusionsThis Danish real-world study evaluating aNSCLC patients after the implementation of targeted therapy and immunotherapy showed that patients with a KRAS G12C mutation had a longer OS from LOT1 and LOT2 compared with Triple WT patients. The longer OS observed in patients with KRAS G12C mutant aNSCLC may be driven by higher PD-L1 expression and consequently more frequent use of immunotherapy.
U2 - 10.1016/j.jtho.2022.07.788
DO - 10.1016/j.jtho.2022.07.788
M3 - Conference abstract in journal
VL - 17
SP - S451
JO - Journal of Thoracic Oncology
JF - Journal of Thoracic Oncology
SN - 1556-0864
IS - 9
ER -
ID: 345502753